Incidental enhancing lesions found on preoperative breast MRI: management and role of second-look ultrasound

Luciani, M. L.; Pediconi, Federica; Telesca, Marianna; Vasselli, Federica; Casali, Valeria; Miglio, Elena; Passariello, Roberto; Catalano, Carlo

doi:10.1007/s11547-011-0630-8

Cited by 32 publications

(25 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No report on item4 was found in four studies (Fischer et al 1999;Goerres et al 2003;Kneeshaw et al 2006;Luciani et al 2011). Results of "no" on item 6 were shown in seven studies (Stomper et al 1995;Helbich et al 1997;Goerres et al 2003;Kneeshaw et al 2006;Pediconi et al 2007;Woodhams et al 2010;Luciani et al 2011) and no report in one study (Martincich et al 2011).…”

Section: Methodological Quality Of Studiesmentioning

confidence: 88%

“…Because the dosage unit of contrast media can't be translated, that is to say, the absolute difference on dosage among these studies is unknown, 2 articles were rejected. 17 studies (Fobben et al, 1995;Stomper et al, 1995;Fenlon et al, 1997;Helbich et al, 1997;Fischer et al, 1999;Alamo et al, 2001;Kawashima et al, 2001;Goerres et al, 2003;Knopp et al, 2003;Pediconi et al, 2005;Sardanelli et al, 2005;Kneeshaw et al, 2006;Pediconi et al, 2007;Pediconi et al, 2008;Woodhams et al, 2010;Luciani et al, 2011;Martincich et al, 2011) with 1934 patients were included based on the inclusion criteria and the data integrity.…”

Section: Literature Searchmentioning

confidence: 99%

“…Four references (Knopp et al 2003;Pediconi et al 2005;Pediconi et al 2008;Martincich et al 2011) reported available data on these two agents. Three references (Sardanelli et al 2005;Pediconi et al 2007;Luciani et al 2011) only reported relevant data on gadobenate dimeglumine, and ten studies (Fobben et al 1995;Stomper et al 1995;Fenlon et al 1997;Helbich et Table 2…”

Section: Description Of Studiesmentioning

confidence: 99%

See 2 more Smart Citations

Comparison of Gadobenate Dimeglumine and Gadopentetate Dimeglumine for Breast MRI Screening: a Meta-analysis

Yang¹,

Han²,

Ye³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Section: Methodological Quality Of Studiesmentioning

confidence: 88%

Section: Literature Searchmentioning

confidence: 99%

Section: Description Of Studiesmentioning

confidence: 99%

See 1 more Smart Citation

Comparison of Gadobenate Dimeglumine and Gadopentetate Dimeglumine for Breast MRI Screening: a Meta-analysis

Yang¹,

Han²,

Ye³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…15,[19][20][21][22][23][24][25][26] Ultrasound lesion detection is influenced by lesion echo texture compared with breast background tissue and by lesion MRI appearance. A higher correlation of second-look ultrasound for mass lesions rather than non-mass ones has been reported.…”

Section: Discussionmentioning

confidence: 99%

Supine breast US: how to correlate breast lesions from prone MRI

Telegrafo¹,

Rella²,

Ianora³

et al. 2016

BJR

View full text Add to dashboard Cite

Objective: To evaluate spatial displacement of breast lesions from prone MR to supine ultrasound positions, and to determine whether the degree of displacement may be associated with breast density and lesion histotype. Methods: 380 patients underwent breast MR and secondlook ultrasound. The MR and ultrasound lesion location within the breast gland, distances from anatomical landmarks (nipple, skin and pectoral muscle), spatial displacement (distance differences from the landmarks within the same breast region) and region displacement (breast region change) were prospectively evaluated. Differences between MR and ultrasound measurements, association between the degree of spatial displacement and both breast density and lesion histotypes were calculated. Results: In 290/380 (76%) patients, 300 MR lesions were detected. 285/300 (95%) lesions were recognized on ultrasound. By comparing MR and ultrasound, spatial displacement occurred in 183/285 (64.3%) cases while region displacement in 102/285 (35.7%) cases with a circumferential movement along an arc centred on the nipple, having supine ultrasound as the reference standard.

show abstract

“…Our experience also supports this conclusion. However, some reports did not demonstrate a correlation between SLUS and diagnosis of malignancy (23)(24)(25). Despite the differences, all reports indicate that the absence of a US correlation is not a sufficient condition for ruling out malignancy.…”

Section: • January-february 2015 • Diagnostic and Interventional Radimentioning

confidence: 94%

Follow-up design of unexpected enhancing lesions on preoperative MRI of breast cancer patients

Cheung¹,

Moon²

2015

Diagn Interv Radiol

View full text Add to dashboard Cite

second-look ultrasound (SLUS) was recommended for 84 of 312 breast cancer patients having unexpected enhancing lesions on MRI. SLUS was performed for 85 unexpected enhancing lesions in 72 patients. We performed a retrospective review to determine the size, lesion type, enhancement kinetic curve, and location in relation to the index cancer. We obtained the pathologic outcome of the detected lesions and in case of a negative finding on SLUS, we performed follow-up examinations for at least two years. RESULTSOf 85 unexpected lesions, 72 (85%) were detected on SLUS. In total, 41 lesions (56.9%) were confirmed as malignant and 31 lesions (43.6%) as benign. Cancer rate was statistically higher in lesions having type III enhancement pattern, located at the same quadrant as the index cancer. However, no significant association was observed between the cancer rate and the lesion size and type. None of the 13 negative cases on SLUS developed cancer on follow-up. CONCLUSIONIn case of unexpected enhancing lesions on preoperative MRI of breast cancer patients, SLUS can be useful to find out the matched lesion. Lesions with type III enhancement pattern or those located at the same quadrant as the index cancer should be considered as a separate cancer. In the absence of any suspicious findings on SLUS, patient may be followed up with confidence. Dynamic contrast-enhanced magnetic resonance imaging (MRI) has been the most accurate technique for the detection and delineation of invasive and some in situ breast cancers (1-6). Despite the high sensitivity of MRI (83%-100%), the reported specificity of this modality is relatively low and ranges from 40% to 80% (7,8). MRI identifies additional lesions much more frequently than other imaging modalities do (9). On preoperative MRI of breast cancer patients, other enhancing lesions are frequently detected in addition to the index cancer. Since the probability of malignancy is high for additionally detected lesions on MRI of breast cancer patients, MRI-guided percutaneous biopsy is a reasonable next step, but it is an expensive and time-consuming procedure, and it is not yet widely available all over the world. Alternatively, ultrasonography (US)-guided biopsy is preferable, because it is less expensive and more convenient for the patients.Second-look ultrasound (SLUS) is a reevaluation method for MRI-detected lesions with the information provided by MRI. Sometimes, SLUS is used even when there is no antecedent US examination. This technique has become increasingly important for detecting unexpected enhancing lesions on MRI, especially for breast cancer patients.Several reports demonstrated the usefulness of SLUS (5, 10, 11). If a lesion can be detected on SLUS, a new malignant lesion can be differentiated from a false-positive enhancing lesion on MRI to conclude the diagnostic workup. Also US guidance can be used for biopsy instead of MRI guidance. Nevertheless, few studies have reported the characterization and meaning of additionally detected lesions on preoperative MRI and SLUS of ...

show abstract

Incidental enhancing lesions found on preoperative breast MRI: management and role of second-look ultrasound

Abstract: Second-look US is a confirmatory method for incidental findings on breast MRI, particularly for mass-like lesions.

Cited by 32 publications

References 39 publications

Comparison of Gadobenate Dimeglumine and Gadopentetate Dimeglumine for Breast MRI Screening: a Meta-analysis

Comparison of Gadobenate Dimeglumine and Gadopentetate Dimeglumine for Breast MRI Screening: a Meta-analysis

Supine breast US: how to correlate breast lesions from prone MRI

Follow-up design of unexpected enhancing lesions on preoperative MRI of breast cancer patients

Contact Info

Product

Resources

About